Renalytix Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RENX.L research report →
Companyrenalytix.com
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
- CEO
- James R. McCullough
- IPO
- 2018
- Employees
- 102
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $5.87M
- P/E
- -0.33
- P/S
- 9.85
- P/B
- -1.43
- EV/EBITDA
- -0.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 6.82%
- Op Margin
- -1293.49%
- Net Margin
- -1461.60%
- ROE
- -631.25%
- ROIC
- -4347.72%
Growth & Income
- Revenue
- $3.00M · 31.06%
- Net Income
- $-20,400,000 · 39.02%
- EPS
- $-0.21 · 32.26%
- Op Income
- $-17,200,000
- FCF YoY
- 40.56%
Performance & Tape
- 52W High
- $15.50
- 52W Low
- $1.60
- 50D MA
- $2.07
- 200D MA
- $5.38
- Beta
- 1.82
- Avg Volume
- 1.08M
Get TickerSpark's AI analysis on RENX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RENX.L Coverage
We haven't published any research on RENX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RENX.L Report →